CASE PRESENTATION: A 72-year-old man presented to our ED less than 24 hours following the acute onset of nausea, vomiting, and diarrhea. Within 12 hours of symptom onset, he noted bilateral lower extremity pain and swelling. His pain was associated with a new violaceous irregular rash on the anterior aspect of both feet and legs. There was no history of inciting trauma or recent wounds. In addition, there was no history of consumption of raw or undercooked food (including seafood) or recent change in food source. There was accompanying fever and chills for the same duration and painful swelling of his left thumb. His comorbidities included stage IIIb classical Hodgkin lymphoma diagnosed 4 months prior. His last dose of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy was 4 days before presentation. He had previously failed anti-CD30 monoclonal therapy resulting from attributed pancolitis. CHEST 2020; 157(2):e41-e45
Physical Examination
On arrival, his vitals were: BP 70/40 mm Hg; heart rate, 130 to 140 beats/min with a temperature of 38.3 C, and oxygen saturation 97% on ambient air. He was cachectic and chronically ill-appearing in painful distress but fully alert and coherent. Mucous membranes were pale, moist, and anicteric. Abdomen was scaphoid, soft, mildly diffusely tender, and without rebound, organomegaly, or palpable masses. Musculoskeletal examination was significant for tender nonblanchable retiform ecchymosis on the dorsal aspect of both feet and legs with hemorrhagic bullae and irregular purpura with swelling of the left thenar eminence (Fig 1A,C,D) . The hemorrhagic bullae on the dorsum of both feet progressed within 2 h of presentation ( Fig 1B) . His neurological examination was nonfocal.
Diagnostic Studies
Initial laboratory data were significant for WBC, 18,000 m/L; hemoglobin, 11.8 g/dL; platelet count, 43,000/mL; serum lactate, 7.0 mmol/L; and creatine phosphokinase, 544 U/L (normal range, 11-204 U/L), which rose to 2,216 U/L on repeat testing in 6 h. Peripheral blood cultures were sent. His diarrhea had resolved on presentation, and no stool samples were available for testing. Broad-spectrum antibiotics were started within 1 h of presentation. CT imaging noted progression of his pancolitis and lower extremity cellulitis with myositis and possible abscess formation in the left vastus medialis (Fig 2) . Limited surgical debridement revealed nonpurulent serosanguinous fluid.
What is the diagnosis?
What is the next step in management? 
Diagnosis: Vibrio vulnificus septicemia following gastroenteritis with diffuse soft tissue infection Next step: The next step would be empiric coverage with doxycycline 100 mg twice daily plus ceftazidime 2 g IV every 8 h, surgical debridement, and incision and drainage of any abscesses as well as supportive medical care.
Discussion
Vibrio species infections are 1 of the most common foodborne illnesses in the United States. Vibrio vulnificus results in the most hospitalizations and mortality of the Vibrio species. V vulnificus infection manifests in 1 of 3 forms in human hosts: gram-negative septicemia often resulting from consumption of raw or undercooked seafood, a necrotizing soft-tissue infection following direct inoculation after trauma, and a selflimiting gastroenteritis.
Primary septicemia is the presenting feature in 40% to 60% of cases of V vulnificus infection. About 27% to 45% of patients present with wound infections following trauma. Most cases (> 90%) of septicemia occur after a GI illness. Patients often report having consumed raw oysters within 2 weeks of presentation; however, about 10% to 19% of patients deny raw oyster exposure, but may have consumed another shellfish. In larger case series, an exposure (GI, wound, or otherwise) cannot be determined in approximately 10% of patients.
Vibrio are motile, gram-negative, curved rods. The name vulnificus comes from the Latin word for 'wounding'. V vulnificus is isolated in saltwater with temperatures between 17 and 20 C (62 -68 F). V vulnificus has a number of virulence factors that allow survival in aquatic settings and human hosts. These factors include adhesion proteins, capsular polysaccharides, cytotoxicity, and acquisition of iron. In addition to these virulence factors, V vulnificus produces extracellular proenzymes that break down to metalloproteinase and caseinolytic protease leading to fibrinolysis and destruction of collagen in blood vessel basement membranes. This manifests as ecchymosis and hemorrhagic bullae.
Purpura is not a diagnosis, but a manifestation of a nonspecific underlying process. It represents leakage of RBCs from blood vessels into skin and soft tissues. Purpura is nonblanchable, differentiating it from other violaceous lesions that result from vascular dilatation. Extensive purpura is often a marker of a potentially serious or life-threatening condition. Specific examples include disseminating intravascular coagulation, thrombotic thrombocytopenia purpura, leukemic syndromes, or meningococcal sepsis. A thorough history and physical examination (with focus on timeline, risk factors, and lesion description) with focused laboratory tests (eg, platelets, prothrombin time/international chestjournal.org e43 normalized ratio, partial thromboplastin time, liver function tests, D-dimer, fibrin degradation products) can narrow the differential and indicate possibly lethal diagnoses.
As previously mentioned, the spectrum of clinical presentations of V vulnificus ranges from GI illness, necrotizing wound infection, and septic shock with end-organ dysfunction. The associated mortality rises from 0% to 55% with increasing severity. Patients with septicemia require supportive care, including fluid resuscitation and vasopressors. There is often rapid clinical deterioration with manifestation of soft-tissue necrosis within 6 to 24 h of symptom onset. Between 50% and 90% of patients with septicemia manifest the characteristic hemorrhagic bullous skin lesions, and 30% and 70% have a preceding GI illness. Progression to multiorgan failure occurs shortly thereafter. Immunocompromised states increase the risk of V vulnificus infection, particularly septicemia. Risk factors include hepatitis B and C infection, liver disease (including cirrhosis), end-stage renal impairment, diabetes, and malignancy.
Soft-tissue infection from V vulnificus ranges from superficial cutaneous infection to cellulitis or even necrotizing fasciitis. Most cases have an inciting skin trauma while in saltwater or handling associated sea creatures (such as lobsters and crabs). The mainstay of treatment is surgical debridement in combination with broad-spectrum antimicrobials. Elevation in serum creatinine phosphokinase is directly related to mortality. Even with early intervention, there is still significant mortality and morbidity requiring major limb amputation.
Aggressive soft-tissue infection is not unique to V vulnificus species. Other causative bacteria are: Streptococcus pyogenes, Pseudomonas species, and gas-forming organisms such as Clostridium perfringens and Aeromonas hydrophila. Differentiating between these organisms on the basis of skin findings alone is difficult and relies on the clinical scenario, with confirmation from culture specimens. V vulnificus can often be differentiated from other bacterial causes of soft-tissue infections by early hemorrhagic bullae. Given the constellation of an immunocompromised host with hemorrhagic bullae or myonecrosis, there should be a high clinical suspicion for V vulnificus infection. It is prudent to investigate for possible undercooked seafood ingestion or open water exposure.
V vulnificus shows susceptibility to tetracycline, ampicillin, cephalosporins, erythromycin, gentamicin, and norfloxacin in vitro. Usual treatment regimens for V vulnificus consist of a combination of a tetracycline and an aminoglycoside in contrast to typical empiric gramnegative coverage that includes an antipseudomonal cephalosporin or beta-lactam/beta-lactamase inhibitor or carbapenem.
Clinical outcomes in V vulnificus infections are directly linked to speed of recognition and treatment initiation. This requires physician awareness and a high index of suspicion. It will have a direct effect on prognosis given the increasing incidence of Vibrio foodborne illness and cases in previous nonendemic areas. Recommendations for reducing the risk of V vulnificus infection are to avoid consumption of raw or undercooked seafood (especially raw oysters). Because of easy transport of food items, it is difficult to limit dietary practices to specific geographic locations. All patients with immunocompromising conditions should be advised to avoid these foods.
Clinical Course
IV vancomycin, cefepime, and metronidazole were commenced after blood cultures were obtained. Given the patient's immunocompromised state and exposure to health-care settings, the decision was made to cover for methicillin-resistant Staphylococcus aureus in addition to Pseudomonas species. Considering his pancolitis and lower extremity wounds, metronidazole was added for pathogenic anerobic coverage. He remained hypotensive despite sepsis protocol fluid resuscitation and quickly required multiple vasopressor agents.
Shortly after admission to the medical ICU, gram stain results showed gram-negative rods and thus gentamicin was added for synergy given his critical status. Additionally, hydrocortisone 50 mg IV every 6 h was started. Extensive surgical debridement was deferred because of the lack of evidence of myonecrosis at the time of general surgery evaluation. At this point, it was thought that his clinical picture was related to severe gram-negative sepsis with a hemorrhagic rash resulting from thrombocytopenia from sepsis. The most likely source was presumed to be his colitis. Laboratory data to rule out disseminated intravascular coagulation was sent on admission, including: fibrinogen 432 mg/dL
(179-402 mg/dL), partial thromboplastin time, 32.5 s (20.9-29.7 s). The remainder of coagulation studies were prothrombin time, 13.5 s (9.2-11.9 s); international normalized ratio 1.37 (0.85-1.18).
Despite maximal supportive care (including mechanical ventilation), he developed worsening multiorgan dysfunction and hemodynamics while on 3 vasopressor agents. His family decided to respect previously discussed goals of care and transition him to hospice by the second admission day. Blood cultures isolated pansensitive V vulnificus from both anaerobic bottles posthumously.
In hindsight, given his immunocompromised state and the rapid progression of his skin lesions following a GI illness, we could have been clued into the diagnosis earlier.
Clinical Pearls
1. Presented with the combination of an immunocompromised host and recent GI illness with hemorrhagic bullae or myonecrosis, have a high clinical suspicion for V vulnificus infection, even in the absence of raw oyster or seafood exposure.
2. In up to 10% of cases of V vulnificus infection, an exposure cannot be determined.
3. Usual recommended treatment is initiation of antimicrobials (a tetracycline in combination with an aminoglycoside), surgical debridement, and supportive care. However, despite these interventions, morbidity and mortality remain high.
4. All patients with immunocompromising conditions should be advised to avoid raw or undercooked seafood. This is in addition to the traditionally suspected patients with hepatitis B and C infection or cirrhosis.
5. Clinical outcomes in V vulnificus infections are directly linked to speed of recognition and treatment initiation.
